All Blogs

Jul 09, 2025

Empasiprubart significantly delayed IVIg retreatment and improved grip strength and patient-reported outcomes in both MMN cohorts. Biomarker shifts, including reduced serum NfL levels, indicate axonal preservation and reinforce the neuroprotective potential of C2 inhibition. At European Academy of Neurology...

Jul 09, 2025

Riliprubart demonstrated meaningful clinical benefit across all enrolled cohorts—SoC-Treated, SoC-refractory, and SoC-naïve—with improvement in functional measures (INCAT, I-RODS, MRC-SS, grip strength). Encouraged by consistent Phase II results, two global Phase III trials in CIDP have now been launched, posit...

Jul 09, 2025

Semaglutide 7.2 mg led to up to 21% weight loss, with one-third of participants losing ≥25% body weight in the STEP UP trial. The STEP UP findings further strengthen the evidence supporting WEGOVY’s ability to deliver substantial weight loss and meaningful health benefits for individuals with obesity. WEGOV...

Jul 09, 2025

A new oral anti-diabetes pill, orforglipron, shows similar effectiveness to injectable GLP-1 drugs in a Phase III trial. Orforglipron significantly reduced A1c over 40 weeks in adults with early Type 2 diabetes, according to the results of ACHIEVE-1. At ADA 2025, Eli Lilly showcased promising Phase III data...

Jul 09, 2025

Zimislecel (VX-880) is an investigational stem cell-derived islet cell therapy for T1D patients with severe hypoglycemia and impaired awareness. It aims to restore insulin production and glucose regulation. Delivered via hepatic portal vein infusion, it requires immunosuppression and holds multiple regulatory desi...

Jul 09, 2025

MariTide is a novel peptide-antibody conjugate designed to treat obesity and T2Ds by activating GLP-1 receptors and blocking GIP receptors. Its dual mechanism and long half-life may enhance durability and help prevent weight regain.  Preclinical studies show greater weight loss with this combined approach ...

Jul 09, 2025

MET-097i is the lead investigational therapy from Metsera, designed as a fully biased GLP-1 receptor agonist with ultra-long-acting properties. Administered via SC injection, it leverages Metsera’s proprietary HALO platform and has shown a preliminary half-life of 15–16 days, indicating the potential for once-mont...

Jul 09, 2025

In the Phase I study, eloralintide led to body weight reductions of up to 11.3% over just 12 weeks in individuals with obesity, demonstrating early efficacy that aligns with emerging expectations for amylin-based therapies. Ongoing trials evaluating the therapy both as a monotherapy and in combination with GLP-...

Jul 09, 2025

CagriSema, a once-weekly combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide, offers a dual mechanism targeting both appetite suppression and glycemic regulation. Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with T2...

Jul 09, 2025

Evolocumab (REPATHA) is a monoclonal antibody targeting PCSK9, leading to increased recycling of LDL receptors and significant reductions in LDL cholesterol levels. Its use in patients already on statins offers incremental LDL-C lowering, making it particularly useful in high-risk populations like T1D, where re...